Magnetic nanoparticles for cancer therapy

Nanotechnology Reviews

Volumn 2, Issue 4, 2013, Pages 395-409

  Dürr, Stephan ^a   Janko, Christina ^a   Lyer, Stefan ^a   Tripal, Philipp ^a   Schwarz, Marc ^a   Zaloga, Jan ^a   Tietze, Rainer ^a   Alexiou, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cancer drug resistance; Cancer therapy; Drug delivery; Hyperthermia; Magnetic nanoparticles

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; DRUG DELIVERY; HYPERTHERMIA THERAPY; MAGNETIC FIELDS; NANOPARTICLES; NUCLEIC ACIDS; ONCOLOGY; POPULATION STATISTICS; TARGETED DRUG DELIVERY;

ALTERNATING MAGNETIC FIELD; CANCER DRUG; CANCER THERAPY; CHEMOTHERAPEUTIC AGENTS; DRUG DELIVERY SYSTEM; HYPERTHERMIA; MAGNETIC NANO-PARTICLES; THERAPEUTIC OUTCOMES;

NANOMAGNETICS;

EID: 84884288005     PISSN: 21919089     EISSN: 21919097     Source Type: Journal    
DOI: 10.1515/ntrev-2013-0011     Document Type: Review

References (91)

1. Grodzinski P. The Workings of NCI nanotechnology alliance for cancer-an opportunity for a new class of diagnostic and therapeutic solutions based on nanotechnology. Salt Lake City, USA, 2007.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
3. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs 2012, 23, 765-776.
4. NICE lehnt weitere krebsmedikamente ab. Dt Ärzteblatt, 2010. Available at http://www.arzteblatt.de/nachtfricten/43932/nice-lehnt-weithre-krebsmedikamente-ab.
5. Tiwari M. Nano cancer therapy strategies. J. Cancer Res. Ther. 2012, 8, 19-22.
6. Durr S, Tietze R, Lyer S, Lyer S, Alexiou C. Nanomedicine in otorhinolaryngology-future prospects. Laryngorhinootologie 2012, 91, 6-12.
7. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 2003, 348, 2491-2499.
8. Alexiou C, Tietze R, Schreiber E, Lyer S. Nanomedicine: magnetic nanoparticles for drug delivery and hyperthermia-new chances for cancer therapy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010, 53, 839-845.
9. Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int. J. Hyperthermia 2008, 24, 467-474.
10. European Technology Platform on Nanomedicine. Nanomedicine-nanotechnology for health. In Nanomedicine ETPo ed., Luxembourg, 2006.
11. A rzteblatt D. Available at: http://www.aerzteblatt.de/studieren/nachrichten/51842/Krebs-kostet-in-Europa-120-Milliarden-Euro-pro-Jahr. In; 2012.
12. EU-Europ a ische Kommission (2009c). Die Auswirkungen der demographischen Alterung in der EU bew a ltigen, Mitteilung der Kommission, EU KOM(2009c) 180 endg u ltig.
13. Klostergaard J, Seeney CE. Magnetic nanovectors for drug delivery. Maturitas 2012, 73, 33-44.
14. Widder KJ, Senyel AE, Scarpelli GD. Magnetic microspheres: a model system of site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. 1978, 158, 141-146.
15. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J. Am. Soc. Nephrol. 2008, 19, 1599-1605.
16. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug. Deliv. Rev. 2010, 62, 284-304.
17. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol. Pharm. 2008, 5, 316-327.
18. Chao X, Zhang Z, Guo L, Zhu J, Peng M, Vermorken AJM, Van de Ven WJM, A Chen C, Cui mail Y. A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy. PLoS One 2012, 7, e40388.
19. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J. Control. Release 2011, 155, 393-399.
20. Verma NK, Crosbie-Staunton K, Satti A, Crosbie-Staunton K, Satti A, Gallagher S, Ryan KB, Doody T. Magnetic core-shell nanoparticles for drug delivery by nebulization. J. Nanobiotechnol. 2013, 11, 1-25.
21. Hiraiwa K, Ueda M, Takeuchi H, Oyama T, Irino T, Yoshikawa T, Kondo A, Kitagawa Y. Sentinel node mapping with thermoresponsive magnetic nanoparticles in rats. J. Surg. Res. 2012, 174, 48-55.
22. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellstrom I, Kroll RA, Neuwelt EA. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am. J. Neuroradiol. 1996, 17, 411-418.
23. Wust P, Gneveckow U, Johannsen M, Bohmer D, Henkel T, Kahmann F, Sehouli J, Felix R, Ricke J, Jordan A. Magnetic nanoparticles for interstitial thermotherapy-feasibility, tolerance and achieved temperatures. Int. J. Hyperthermia 2006, 22, 673-685.
24. Agemy L, Friedmann-Morvinski D, Kotamrajua VR, Sugahar RL, Girard OM, Mattrey RF, Verma IM, Ruoslahti E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. USA 2011, 108, 17450-17455.
25. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
26. Alphandery E, Faure S, Seksek O, Guyot F, Chebbi I. Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy. ACS Nano 2011, 5, 6279-6296.
27. Balivada S, Rachakatla RS, Wang H, Samarakoon TN, Dani RK, Pyle M, Kroh FO, Walker B, Leaym X, Koper OB, Tamura M, Chikan V, Bossmann SH, Troyer DL. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer 2010, 10, 119.
28. Bruners P, Braunschweig T, Hodenius M, Pietsch H, Penzkofer T, Baumann M, Gunther RW, Schmitz-Rode T, Mahnken AH. Thermoablation of malignant kidney tumors using magnetic nanoparticles: an in vivo feasibility study in a rabbit model. Cardiovasc. Intervent. Radiol. 2010, 33, 127-134.
29. Chen J, Wu H, Han D, Xie C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 2006, 231, 169-175.
30. DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, Gruettner C, Adamson GN, Ivkov R. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. J. Nucl. Med. 2007, 48, 437-444.
31. Dutz S, Kettering M, Hilger I, Muller R, Zeisberger M. Magnetic multicore nanoparticles for hyperthermia-influence of particle immobilization in tumour tissue on magnetic properties. Nanotechnology 2011, 22: 265102 (7pp).
32. Fang C, Veiseh O, Kievit F, Bhattarai N, Wang F, Stephen Z, Li C, Lee D, Ellenbogen RG, Zhang M. Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior. Nanomedicine (Lond) 2010, 5, 1357-1369.
33. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Invest. Radiol. 2002, 37, 580-586.
34. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010, 70, 7553-7561.
35. Li XS, Li WQ, Wang WB. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment. Cancer Biother. Radiopharm. 2007, 22, 772-778.
36. Li Z, Xiang J, Zhang W, Fan S, Wu M, Li X, Li G. Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther. 2009, 16, 423-429.
37. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv. Drug Deliv. Rev. 2011, 63, 1300-1331.
38. Rainov NG, Zimmer C, Chase M, Chase M, Kramm CM, Chiocca EA, Weissleder R, Breakefield XO. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum. Gene Ther. 1995, 6, 1543-1552.
39. Shen LF, Chen J, Zeng S, Zhou RR, Zhu H, Zhong MZ, Yao RJ, Shen H. The superparamagnetic nanoparticles carrying the E1A gene enhance the radiosensitivity of human cervical carcinoma in nude mice. Mol. Cancer Ther. 2010, 9, 2123-2130.
40. Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int. J. Cancer 2005, 116, 624-633.
41. Tang QS, Chen DZ, Xue WQ, Barry S, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S, Xiang JY, Gong YC, Zhang L, Guo CQ. Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo. Int. J. Nanomed. 2011, 6, 3077-3085.
42. Toraya-Brown S, Sheen MR, Baird JR, Barry S, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S. Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr. Biol. (Camb) 2013, 5, 159-171.
43. Tresilwised N, Pithayanukul P, Mykhaylyk O, Holm PS, Holzmuller R, Anton M, Thalhammer S, Adiguzel D, Doblinger M, Plank C. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol. Pharm. 2010, 7, 1069-1089.
44. Wang L, Dong J, Ouyang W, Wang X, Tang J. Anticancer effect and feasibility study of hyperthermia treatment of pancreatic cancer using magnetic nanoparticles. Oncol. Rep. 2012, 27, 719-726.
45. Wu YN, Chen DH, Shi XY, Lian CC, Wang TY, Yeh CS, Ratinac KR, Thordarson P, Braet F, Shieh DB. Cancer-cell-specific cytotoxicity of non-oxidized iron elements in iron core-gold shell NPs. Nanomedicine 2011, 7, 420-427.
46. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldofner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur. Urol. 2007, 52, 1653-1661.
47. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011, 103, 317-324.
48. Namiki Y, Namiki T, Yoshida H, Ishii Y, Tsubota A, Koido S, Nariai K, Mitsunaga M, Yanagisawa S, Kashiwagi H, Mabashi Y, Yumoto Y, Hoshina S, Fujise K, Tada N. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat. Nanotechnol. 2009, 4, 598-606.
49. Shanta Singh N, Kulkarni H, Pradhan L, Bahadur D. A multifunctional biphasic suspension of mesoporous silica encapsulated with YVO(4):Eu(3 + ) and Fe(3)O(4) nanoparticles: synergistic effect towards cancer therapy and imaging. Nanotechnology 2013, 24, 065101.
50. Fang C, Kievit FM, Veiseh O, Stephen ZR, Wang T, Lee D, Ellenbogen RG, Zhang M. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J. Control. Release 2012, 162, 233-241.
51. Yallapu MM, Othman SF, Curtis ET, Curtis ET, Gupta BK, Jaggi M, Chauhan SC. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32, 1890-1905.
52. Guo D, Wu C, Hu H, Wang X, Li X, Chen B. Study on the enhanced cellular uptake effect of daunorubicin on leukemia cells mediated via functionalized nickel nanoparticles. Biomed. Mater. 2009, 4, 025013.
53. Durr S, Lyer S, Mann J, Janko C, Tietze R, Schreiber E, Herrmann M, Alexiou C. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res. 2012, 32, 1983-1989.
54. Alexiou C, Diehl D, Henninger P, Iro H, Rockelein R, Schmidt W, Weber H. A high field gradient magnet for magnetic drug targeting. IEEE T. Appl. Supercon. 2006, 16, 1527-1530.
55. Tietze R, Rahn H, Lyer S, Schreiber E, Mann J, Odenbach S, Alexiou C. Visualization of superparamagnetic nanoparticles in vascular tissue using XmuCT and histology. Histochem. Cell Biol. 2011, 135, 153-158.
56. Seliger C, Jurgons R, Wiekhorst F, Eberbeck D, Trahms L, Iro H, Alexiou C. In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J. Magn. Magn. Mater. 2007, 311, 358-362.
57. Alexiou C, Jurgons R, Schmid R, Erhardt W, Parak F, Bergemann C, Iro H. Magnetic drug targeting-a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies. HNO 2005, 53, 618-622.
58. Alexiou C, Arnold W, Hulin P, Kleinb RJ, Renz H, Parak FG, Bergemann C, Lubbe AS. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J. Magn. Magn. Mater. 2001, 225, 187-193.
59. Rahn H, Gomez-Morilla I, Jurgons R, Alexiou Ch, Odenbach S. Microcomputed tomography analysis of ferrofluids used for cancer treatment. J. Phys. Condens. Matter 2008, 20: 204152 (4pp).
60. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 2003, 11, 139-149.
61. Lyer S, Tietze R, Jurgons R, Struffert T, Engelhorn T, Schreiber E, Dorfler A, Alexiou C. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles-a pilot study. Anticancer Res. 2010, 30, 1553-1557.
62. Wang Y, Zhang Y, Du Z, Wu M, Zhang G. Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots. Int. J. Nanomed. 2012, 7, 2315-2324.
63. Yang C, Rait A, Pirollo KF, Dagata JA, Farkas N, Chang EH. Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo. Nanomedicine 2008, 4, 318-329.
64. Klein S, Sommer A, Distel LV, Neuhuber W, Kryschi C. Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation. Biochem. Biophys. Res. Commun. 2012, 425, 393-397.
65. Li C, Li L, Keates AC. Targeting cancer gene therapy with magnetic nanoparticles. Oncotarget 2012, 3, 365-370.
66. Qi L, Wu L, Zheng S, Wang Y, Fu H, Cui D. Cell-penetrating magnetic nanoparticles for highly efficient delivery and intracellular imaging of siRNA. Biomacromolecules 2012, 13, 2723-2730.
67. Muthana M, Scott SD, Farrow N, Morrow F, Murdoch C, Grubb S, Brown N, Dobson J, Lewis CE. A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Ther. 2008, 15, 902-910.
68. Chen L, Mashimo T, Iwamoto C, Okudera H, Omurzak E, Ganapathy HS, Ihara H, Zhang J, Abdullaeva Z, Takebe S, Yoshiasa A. Synthesis of novel CoC(x)@C nanoparticles. Nanotechnology 2013, 24, 045602.
69. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley ' s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley ' s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. Suppl. 1953, 276, 1-103.
70. Wust P, Hegewisch-Becker S, Issels R. Hyperthermia: current status and therapeutic results. Dtsch. Med. Wochenschr. 2003, 128, 2023-2029.
71. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 2007, 19, 418-426.
72. Issels RD. Hyperthermia adds to chemotherapy. Eur. J. Cancer 2008, 44, 2546-2554.
73. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB Selective inductive heating of lymph nodes. Ann. Surg. 1957, 146, 596-606.
74. Gonzales-Weimuller M, Zeisberger M, Krishnan KM. Size-dependant heating rates of iron oxide nanoparticles for magnetic fluid hyperthermia. J. Magn. Magn. Mater. 2009, 321, 1947-1950.
75. Xu Y, Mahmood M, Li Z, Dervishi E, Trigwell S, Zharov VP, Ali N, Saini V, Biris AR, Lupu D, Boldor D, Biris AS. Cobalt nanoparticles coated with graphitic shells as localized radio frequency absorbers for cancer therapy. Nanotechnology 2008, 19, 435102.
76. Rodriguez-Luccioni HL, Latorre-Esteves M, Mendez-Vega J, M e ndez-Vega J, Soto O, Rodriguez AR, Rinaldi C, Torres-Lugo M. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int. J. Nanomed. 2011, 6, 373-380.
77. Hedayati M, Thomas O, Abubaker-Sharif B, Zhou H, Cornejo C, Zhang Y, Wabler M, Mihalic J, Gruettner C, Westphal F, Geyh A, Deweese TL, Ivkov R. The effect of cell cluster size on intracellular nanoparticle-mediated hyperthermia: is it possible to treat microscopic tumors? Nanomedicine (Lond) 2013, 8, 29-41.
78. Asin L, Ibarra MR, Tres A, Goya GF. Controlled cell death by magnetic hyperthermia: effects of exposure time, field amplitude, and nanoparticle concentration. Pharm. Res. 2012, 29, 1319-1327.
79. Oliveira H, Perez-Andres E, Thevenot J, Sandre O, Berra E, Lecommandoux S. Magnetic field triggered drug release from polymersomes for cancer therapeutics. J. Control. Release 2013, http://dx.doi.org/10.1016/j.jconre/2013.01.013.
80. Li J, Qu Y, Ren J, Yuan W, Shi D. Magnetocaloric effect in magnetothermally-responsive nanocarriers for hyperthermiatriggered drug release. Nanotechnology 2012, 23, 505706.
81. Koppolu B, Bhavsar Z, Wadajkar AS, Nattama S, Rahimi M, Nwariaku F, Nguyen KT. Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer. J. Biomed. Nanotechnol. 2012, 8, 983-990.
82. Kale SN, Jadhav AD, Verma S, Koppikar SJ, Kaul-Ghanekar R, Dhole SD, Ogale SB. Characterization of biocompatible NiCo2O4 nanoparticles for applications in hyperthermia and drug delivery. Nanomedicine 2012, 8, 452-459.
83. Tietze R, Lyer S, Durr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond) 2012, 7, 447-457.
84. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
85. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998, 27, 187-201.
86. Chen Y, Tang Y, Wang MT, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007, 67, 10361-10367.
87. Cheng J, Wang J, Chen B, Xia G, Cai X, Liu R, Ren Y, Bao W, Wang X. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int. J. Nanomed. 2011, 6, 2123-2131.
88. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
89. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14, 150-163.
90. Morgan SC, Parker CC. Local treatment of metastatic cancer-killing the seed or disturbing the soil ? Nat. Rev. Clin. Oncol. 2011, 8, 504-506.
91. Yang F, Jin C, Yang D, Jiang Y, Li J, Di Y, Hu J, Wang C, Ni Q, Fu D. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur. J. Cancer 2011, 47, 1873-1882.